75 results about "Terbinafine" patented technology

Pharmaceutical formulations suitable for iontophoresis thereof that provide enhanced iontophoretic delivery of an anti-fungal drug to at least one body surface are described. Also described are pharmaceutical formulations suitable for iontophoresis comprising terbinafine and methods for administering terbinafine to a body surface via iontophoresis. In one embodiment, the body surface includes a nail plate and/or the skin.

An improved antifungal composition for topical application to the skin and nails comprises: (1) an allylamine antifungal compound; (2) an aliphatic alcohol substituted with an aromatic substituent in which the allylamine antifungal compound is soluble to a degree that a therapeutically effective concentration of the allylamine antifungal compound can be applied topically in solution; (3) a lower aliphatic alcohol in which the aromatic alcohol is soluble; and (d) water or a water-compatible solvent mixture. The allylamine antifungal compound can be terbinafine or naftifine. The aliphatic alcohol substituted with an aromatic substituent can be benzyl alcohol or phenethyl alcohol. The lower aliphatic alcohol can be ethyl alcohol or isopropyl alcohol. In an alternative, the composition can further comprise an additional antifungal compound. Another aspect of the invention is a method for treatment of a fungal infection of skin or nails comprising administering the antifungal composition of the present invention topically to the skin or nails in an amount therapeutically effective to treat the fungal infection.

The invention provides an antifungal drug composition for external use, and a preparation method of an external preparation, and application of the composition in treating superficial fungal infections, such as tinea manus and pedis, tinea corporis, tinea cruris, tinea unguium, tinea versicolor and oidiomycosis cutis. The drug composition contains terbinafine or pharmaceutical salt thereof, sertaconazole or pharmaceutical salt thereof, and any one or multiple pharmaceutically acceptable excipient. An experimental study shows that the terbinafine or pharmaceutical salt thereof and the sertaconazole or pharmaceutical salt thereof have obvious synergistic effect when the proportion thereof in the drug composition for treating the superficial fungal infections is (1: 10) to (5: 1)(w/w). The antifungal drug composition for treating the superficial fungal infections has the advantages of being good in security, excellent in curative effect, short in treatment course, high in curing rate, low in relapse rate and the like.

A process for the preparation of Terbinafine and salts thereof by reacting 1-chloro-6,6-dimethylhept-2-en-4-yne and N-methyl-N-(1-naphthylmethyl)amine in a basic aqueous medium is disclosed. Also disclosed is a process for the preparation of 1-chloro-6,6-dimethylhept-2-en-4-yne.

A topical composition for treating nail fungal infections that utilizes an acidic antifungal agent with a molecular weight no greater than 170 Daltons in a formulation having a pH less than or equal to the pKa of the acidic antifungal agent plus one. Possible antifungal agents include omadine, octanoic acid, sorbic acid, hexanoic acid, and benzoic acid. The antifungal agent can be combined with a delivery system such as a lacquer, a gel, a patch, or a hydrating system. A second therapeutic agent such as a 5-fluorocystine or terbinafine can be included.

The present invention is directed to a nail lacquer consisting essentially of terbinafine as an antimycotic agent, hydroxypropyl chitosan as film forming agent, water and a lower alkanol as solvents. The invention is also directed to a method for treating onychomycosis by topically administering such a nail lacquer to a patient in need of such a treatment.

The invention provides a synthetic method of terbinafine. Monomethylamine, 1-chloromethyl naphthalene and 1-chloro-6,6-dimethyl-2-heptene-4-alkyne are subjected to a one-step reaction to generate theterbinafine. Particularly, the monomethylamine is slowly added into a solvent, and then an acid-binding agent is added; the 1-chloromethyl naphthalene and the 1-chloro-6,6-dimethyl-2-heptene-4-alkyneare simultaneously slowly dropwise added, and a dropwise adding speed is controlled so as to enable both the 1-chloromethyl naphthalene and the 1-chloro-6,6-dimethyl-2-heptene-4-alkyne to be simultaneously dropwise added up; a temperature control reaction is performed for 2 to 3 hours at a temperature of 10 to 20 DEG C; chloroform is added to extract reaction liquid, vacuum concentration is carried out on an organic layer to a dry state, and ethyl acetate is added into residues to carry out crystallization to obtain the terbinafine. The synthetic method is high in yield, simple in step and convenient to operate, generates few byproducts, and is beneficial to industrial production.

The invention discloses a preparation method of terbinafine hydrochloride, and belongs to the technical field of medicine. According to the method, a monomethylamine aqueous solution and (E)-1, 3 dichloropropene are taken as materials to react to obtain (E)-1-methylamino-3-chlorine-propylene; then (E)-1-methylamino-3-chlorine-propylene reacts with tertiary butyl acetylene to obtain (E)-N-(6, 6-dimethyl-2-heptylene-4-alkynyl) methylamine; and then the (E)-N-(6, 6-dimethyl-2-heptylene-4-alkynyl) methylamine reacts with 1-chlorine-methylnaphthalene to obtain terbinafine, and hydrochloric acid is added for salification to obtain terbinafine hydrochloride. According to the method, materials are easy to get, the cost is low, the preparation method is simple, the yield is high, and the method is suitable for industrial production.

The invention discloses a terbinafine compound preparation for treating eczema, dermatitis, body ringworm, tinea cruris, tinea manus and pedis and the preparation method; the invention mainly uses terbinafine hydrochloride and clobetasol propionate or triamcinolone acetonide acetate, which is further matched with O/W emulsion matrix for the preparation of cream. The invention is characterized by fast onset of action, short treatment course and low recurrence rate for treating skin fungal infection with local inflammatory or chronic eczema.

The invention discloses a compound terbinafine nanomedicine used for treating skin diseases. The grain size of the medicine is 1nm-10nm, and the compound terbinafine nanomedicine comprises the following components: 0.1%-10% of terbinafine, 0.1%-15% of eugenol, 0.1%-5% of erythromycin, 0.1%-10% of oil, 10%-40% of surfactant, 4%-20% of cosurfactant and the balance of distilled water, and the total percentage by weight of the components is 100%. The medicine disclosed by the invention has the advantages of small particle size, low viscosity, good liquidity, stable properties and better percutaneous permeability, and not only has a stronger curative effect on pet dermatomycosis, but also has a strong therapeutical effect on pet bacterial skin diseases and parasitic skin diseases. The compound terbinafine nanomedicine disclosed by the invention is easy to prepare, is low in energy consumption, and can be in mass production without special equipment. The compound terbinafine nanomedicine has wide application prospects in the aspect of pet skin disease treatment.

The present invention discloses the use of allylamine derivatives, such as terbinafine, in the inhibition of cancer cell growth. Also disclosed is the synergistic efficacy of allylamine derivatives in combination with other chemotherapeutically active agents, such as nocodazole, in the inhibition of cancers.

The present invention relates to topical antifungal formulations comprising one or more antifungal (e.g., terbinafine), a lipid and a surfactant, and uses thereof for the treatment of skin and nail fungal infections.

Disclosed is a tinea resisting cream which is used for treating diseases caused by shadow position fungus infection, such as tinea corporis, tinea cruris, extremity corporis. The medicament comprises a dozen of constituents including lauryl alcohol, terbinafine, ethyl p-hydroxybenzoate, Roxithromycin, and methyl ethylene glycol.

The invention discloses a yeast strain promoter with weakened regulation intensity and application thereof. The invention specifically discloses a DNA molecule, and the DNA molecule is a recombinant promoter with reduced or weakened regulation intensity obtained by integrating a heterologous cis-acting regulatory element with a repression effect and a yeast strain inner source endogenous promoter. According to the invention, the intensity of the yeast strain promoter can be effectively reduced by integrating the marO sequence, the gene expression level is reduced from the transcriptional level, and a new tool is provided for reducing the metabolic flux of a branch way, a decomposition way or a derivative way in yeast metabolic engineering. The metabolic flux from squalene to sterol can be effectively reduced by applying the promoter weakening strategy to weakening of a yeast squalene derivation path. The yeast strain for producing squalene, provided by the invention, can realize efficient accumulation of squalene, reduce the fermentation cost and simplify the fermentation process under the condition of not adding additional enzyme inhibitor terbinafine or other effectors, with a very good industrial application prospect.

The present invention discloses a compound of an Terbinafine or the halo-Terbinafine membrane forming gel, which comprises the components of the following weight percentages comprising 0.5 percentage to 7 percentage of alkyl cellulose, 1 percentage to 10 percentage of etherifying agent, 0.5 percentage to 5 percentage of cross linking agent, 0.5 percentage to 5 percentage of accentuator, 75 percentage to 90 percentage of dissolvant0.1 percentage to 5 percentage, of Terbinafine or the halo-Terbinafine. The cross linking agent is the saturated fat or the alcoholic acid, the chemical general formula of which is C_nH_2n+2-m-l(OH)_m(COOH)_l. Among the formula, m or n or 1 is the integer and the n is no less than m, which is no less than 2. 1 is no less than 0 and the result of m plus 1 is 4 to 8. The result of n plus 1 is 4 to 8. In the present invention, the compound of the Terbinafine or the halo-Terbinafine local membrane forming gel is applied for treatment of the local fungus inflammation. A water drain protective membrane with smooth property, firm property, wear-resisting property and duration property is formed on the surface of the ulcer when the present invention is applied. Compared with all kinds of formulations of the Terbinafine or the halo-Terbinafine in the present technique, the membrane formed by the gel compound is not likely to experience fracture, dissolution or corrosion. The membrane has the properties of long maintenance time and slow releasing of the medicine.

The invention discloses a compound clobetasol propionate nano-medicament of which the particle size is 1-100 nanometers. The medicament consists of the following components in percentage by weight: 10.0-50 percent of surfactant, 0-8 percent of cosurfactant, 0.5-20 percent of oil, 0.001-4.0 percent of amitraz, 0.001-4.0 percent of clobetasol propionate, 0.001-10 percent of terbinafine and the balance of distilled water, wherein the total percentage by weight of the components is 100 percent. The medicament has the effects of resisting bacteria, diminishing inflammation, relieving itching and pain, killing mites and treating fungal diseases, eczema and various types of dermatitis caused by fungi such as dermatophyte, microsporosis capitis, acrothesium floccosum, microzyme of monilia and chaff ringworm fungus, and the like. The medicament is a yellow or colorless clear transparent liquid and has the advantages of high stability, high wetting property, good transdermal effect, nontoxicity, non-irritation, high safety, easiness for preparing, low cost and convenience for popularizing.

The invention provides a pharmaceutical composition for treating leuconychia. The pharmaceutical composition is prepared from the following raw materials in parts by weight: 1-15 parts of an active component terbinafine, 1-15 parts of bifonazole, 15-60 parts of a capsule wall material, 5-50 parts of a hydration medium and 10-80 parts of purified water. The prepared pharmaceutical composition for treating leuconychia is high in vesicle solution encapsulation efficiency, high in permeation rate, fast to act, safe and reliable, and has a market development prospect; and the problem that fungi attached to a nail plate of a leuconychia patient cannot be killed due to thick cornifin is solved.

An antifungal liquid composition for topical administration is provided that contains turpentine and at least one of peppermint oil, mineral oil, and essential oil alcohols, and one or more antifungal medications selected from ciclopirox olamine, terbinafine, tolnaftate, microconazole, itraconazole, ketoconazole, econazole, and fluconazole, and optionally one or more antifungal essential oils, and its use in the topical treatment of fungal infection, particularly of the nail.

The invention relates to an animal drug, in particular to a pesticide for animals, which belongs to an external used drug suitable for disinfestation for animals or curing the skin diseases for the animals. The invention adopts the solution that the pesticide includes mandarin oil, hesperetin with purity being more than and equal to 98.6 percent and terbinafine with purity being more than and equal to 99.8 percent, and the proportion among the mandarin oil, the hesperetin and the terbinafine is 100:1 to 2:0.25 to 0.9. During the manufacturing process, the hesperetin and the terbinafine are added into the mandarin oil in sequence according to the proportion, stirred at the normal temperature to be completely dissolved and uniformly mixed to obtain the finished product. The finished product is colorless or faint yellow transparent liquid, has the delicious taste of the orange, has good treatment effect to the skin disease, the fungus diseases, the acariasis and the acarid diseases of animals such as cats, dogs and the like, and has strong repelling and killing action to various mites, lice and flea.

The invention relates to an antifungal composition. The composition includes as follows: a) terbinafine or a pharmaceutically acceptable salt thereof; b) berberine or a pharmaceutically acceptable salt thereof; and c) urea and applications thereof. An application of a drug composition in preparation of drugs for treating fungal infections is also related. The drug composition includes the terbinafine or the pharmaceutically acceptable salt thereof and the berberine or the pharmaceutically acceptable salt thereof; and fungi are selected from trichophyton, fusarium, candida and combinations thereof. The composition can enhance sterilization effects, reduce the using amount of the drugs, shorten the course of treatment or avoid drug resistance.

The invention discloses a terbinafine preparation and applications of the terbinafine preparation in tobacco leaf squalene content improvement, wherein the terbinafine preparation comprises, by weight, 10-20% of terbinafine, 5-8% of tris(dodecyl alcohol polyether-4)phosphate, and the balance of ethanol. According to the present invention, the terbinafine preparation is added during the tobacco growth process, the squalene content in the tobacco leaf can be increased, and the economic value of the tobacco leaf is improved.